

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 February 2009 (12.02.2009)

PCT

(10) International Publication Number
WO 2009/020236 A3

(51) International Patent Classification:

C12N 15/866 (2006.01) A61K 39/015 (2006.01)
A61K 39/145 (2006.01)

(21) International Application Number:

PCT/JP2008/064503

(22) International Filing Date: 6 August 2008 (06.08.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2007-205785 7 August 2007 (07.08.2007) JP

(71) Applicants (for all designated States except US): **EDUCATIONAL FOUNDATION JICHI MEDICAL UNIVERSITY** [JP/JP]; 3311-1, Yakushiji, Shimotsuke-shi, Tochigi, 3290498 (JP). **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **YOSHIDA, Shigeto** [JP/JP]; Jichi Medical University Kyoshokuin Jutaku E-403,1-3, Gion 3-chome, Shimotsuke-shi, Tochigi, 3290434 (JP). **KAWASAKI, Masanori** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **MATSUMOTO, Makoto** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **OHBA, Yoshio** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **SAITO, Masahiro** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **GOTO, Yoshihiro** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **INAGAKI, Katsuya** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **MIZUKOSHI, Masami** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD.,

1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **HARIGUCHI, Norimitsu** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **HIROTA, Kuniko** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(74) Agents: **Saegusa & Partners** et al.; Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka 5410045 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:

16 April 2009

(54) Title: BACULOVIRAL VECTORS WITH A DUAL VERTEBRATE AND BACULOVIRUS PROMOTER CONTROLLING AN IMMUNOGENIC FUSION GENE

(57) Abstract: The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; and pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; and pharmaceuticals containing the recombinant baculovirus as an active ingredient.



WO 2009/020236 A3